RecruitingPhase 1NCT07283770
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
128 participants
Start Date
Dec 9, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria3
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (>) 50 kg
- Male and Female participants of non-childbearing potential
Exclusion Criteria2
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVX-581
Suspension for Oral Administration.
DRUGPlacebo
Suspension for Oral Administration.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07283770
Related Trials
Natural History of Noncirrhotic Portal Hypertension
NCT024177401 location
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT061474141 location
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT044694399 locations
Maralixibat in Patients With Cystic Fibrosis and Constipation
NCT064133681 location